Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
Processes and materials are provided for the detection, diagnosis, or determination of the severity of a neurological injury or condition, including traumatic brain injury, multiple-organ injury, stroke, Alzeimer's disease, Parkinson disease and Chronic Traumatic Encephalopathy (CTE). The processes and materials include biomarkers detected or measured in a biological sample such as whole blood, serum, plasma, or CSF. Such biomarkers include Tau and GFAP proteins, their proteolytic breakdown products, brain specific or enriched micro-RNA, and brain specific or enriched protein directed autoantibodies. The processes and materials are operable to detect the presence of absence of acute, subacute or chronic brain injuries and predict outcome for the brain injury.
1. A process for detecting an autoantibody to glial fibrillary acid protein (GFAP) or a breakdown product thereof comprising: measuring an autoantibody to GFAP or an autoantibody to a GFAP breakdown product in a sample obtained from a subject presenting with clinical symptoms of a traumatic brain injury by contacting the sample with GFAP or a GFAP breakdown product and detecting binding between the autoantibody to GFAP and GFAP or between the autoantibody to the GFAP breakdown product and the GFAP breakdown product, wherein the GFAP is set forth in SEQ ID NO: 114, and wherein the GFAP breakdown product is within 10 amino acids of the cleavage site at amino acid position 59 or 383 set forth in SEQ ID NO: 114.
2. The process of claim 1 , wherein the GFAP breakdown product is selected from the group consisting of: SEQ ID NO: 3, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 4, SEQ ID NO: 141, and SEQ ID NO: 142.
3. The process of claim 1 , wherein the GFAP or GFAP breakdown product is detectably labeled.
4. The process of claim 1 , wherein the sample is blood, serum, plasma, CSF, urine, saliva or tissue.
5. The process of claim 1 , wherein the sample is blood, serum, or plasma.
6. The process of claim 1 , wherein the binding between the autoantibody to GFAP and GFAP or between the autoantibody to the GFAP breakdown product and the GFAP breakdown product is detected using an enzyme linked immunosorbent assay (ELISA) or a western blot.
7. The process of claim 1 , wherein the sample is obtained at least five days after the subject suffers the TBI.
8. The process of claim 1 , wherein the sample is obtained up to 30 days after the subject suffers the TBI.
9. The process of claim 1 , further comprising administering a therapeutic to the subject if binding between the autoantibody to GFAP and GFAP or between the autoantibody to the GFAP breakdown product and the GFAP breakdown product is detected.
10. The process of claim 9 , further comprising:
detecting whether an autoantibody to glial fibrillary acidic protein (GFAP) or an autoantibody to a GFAP breakdown product is present in an additional sample obtained from the subject by contacting the additional sample with GFAP or a GFAP breakdown product and detecting binding between the autoantibody to GFAP and GFAP or between the autoantibody to the GFAP breakdown product and the GFAP breakdown product, wherein the GFAP is set forth in SEQ ID NO: 114 and wherein the GFAP breakdown product is within 10 amino acids of the cleavage site at amino acid position 59 or 383 set forth in SEQ ID NO: 114.
11. The process of claim 1 , further comprising:
detecting whether an autoantibody to glial fibrillary acidic protein (GFAP) or an autoantibody to a GFAP breakdown product is present in an additional sample obtained from the subject by contacting the additional sample with GFAP or a GFAP breakdown product and detecting binding between the autoantibody to GFAP and GFAP or between the autoantibody to the GFAP breakdown product and the GFAP breakdown product, wherein the GFAP is set forth in SEQ ID NO: 114 and wherein the GFAP breakdown product is within 10 amino acids of the cleavage site at amino acid position 59 or 383 set forth in SEQ ID NO: 114.